1832 Asset Management L.P. Purchases 27,760 Shares of Becton, Dickinson and Company $BDX

Key Points

• 1832 Asset Management L.P. increased its holdings in Becton, Dickinson and Company by 10.0% in Q1, acquiring an additional 27,760 shares for a total of 305,950 shares, valued at approximately $70.08 million.
• Insider transactions included sales by EVP David Shan, who sold 1,166 shares for approximately $199,607, indicating a 20.31% decrease in ownership, and Director Claire Fraser, who sold 863 shares valued at about $165,955.
• The company reported strong quarterly earnings with a net income of $3.68 EPS, surpassing estimates, and also declared a quarterly dividend of $1.04 per share, reflecting a yield of 2.1%.

1832 Asset Management L.P. increased its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 10.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 305,950 shares of the medical instruments supplier's stock after acquiring an additional 27,760 shares during the period. 1832 Asset Management L.P. owned about 0.11% of Becton, Dickinson and Company worth $70,081,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Northcape Wealth Management LLC raised its holdings in shares of Becton, Dickinson and Company by 0.5% in the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock worth $2,248,000 after acquiring an additional 51 shares during the last quarter. Alpha Omega Wealth Management LLC raised its holdings in shares of Becton, Dickinson and Company by 5.7% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock worth $225,000 after acquiring an additional 53 shares during the last quarter. Brady Family Wealth LLC raised its holdings in shares of Becton, Dickinson and Company by 1.2% in the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after acquiring an additional 53 shares during the last quarter. Diversified Trust Co raised its holdings in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock worth $272,000 after acquiring an additional 53 shares during the last quarter. Finally, REAP Financial Group LLC raised its holdings in shares of Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock traded up $1.43 during trading hours on Wednesday, hitting $195.50. 1,329,810 shares of the company were exchanged, compared to its average volume of 2,628,961. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The stock has a market capitalization of $56.04 billion, a price-to-earnings ratio of 35.16, a P/E/G ratio of 1.46 and a beta of 0.20. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm has a fifty day simple moving average of $181.58 and a 200 day simple moving average of $194.78.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same period in the previous year, the business earned $3.50 EPS. Becton, Dickinson and Company's revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's payout ratio is currently 74.82%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president directly owned 4,575 shares of the company's stock, valued at $783,194.25. This trade represents a 20.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,214 shares of company stock worth $579,206. Corporate insiders own 0.36% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on BDX. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Barclays decreased their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Stifel Nicolaus decreased their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Bank of America lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective for the company. in a research note on Thursday, May 1st. Finally, William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $211.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.